Oligonucleotides are giving rise to a new generation of therapeutics—and Nitto Avecia is helping lead the way. With more than 25 years’ experience in oligonucleotide development and production, we are the partner of choice for pharmaceutical innovators creating new drugs with the power to transform treatment for a wide range of diseases.

In partnership with Nitto Avecia Pharma Services, Nitto Avecia is the first CMO that offers a comprehensive, end-to-end oligonucleotide solution. This offers the advantage of a single, expert partner handling the entire process—from drug substance through drug product manufacturing—with flexible solutions and consistent reliability and quality.

Biotechnology

Life Sciences

Pharmaceutical

Therapeutics

Nitto Avecia

Marie Laliberte

Kristy Bazaire

Derek Julian

Regina Hill

Brian Murphy Mba

Robert Coulter

Andrew Donaldson

Bethany Wood

Jennifer O'Brien

Kenji Nawa

Keri Dufault

Luke Altenau Cpm

Marc Gomez Caminals

Mark Boyle Mba, Cssbb

Steve Trahan

Theresa Vaughan

Natalia Olive

Michael Amend

Cindy Farnsworth

Michelle Leboeuf

Peter Tenaglia

Bob Gallinaro

Taylor Kleineick

Erica B. Blake

The Research and Development Team at Nitto Avecia is responsible for advancing the development and optimization of oligonucleotide therapeutics. This involves innovative research to enhance drug efficacy and safety, process development to streamline manufacturing, and analytical development to ensure quality and consistency. Team members collaborate closely to translate scientific discoveries into viable pharmaceutical products, ensuring seamless integration from drug substance creation to final drug product manufacturing.

Research and Development Team

Quality Control

Project Management

Research and Development Team

About

Team members

Other teams at Nitto Avecia

Quality Control

Project Management